CN106456778A - 在神经创伤性病患中使用因子xii抑制剂进行治疗 - Google Patents

在神经创伤性病患中使用因子xii抑制剂进行治疗 Download PDF

Info

Publication number
CN106456778A
CN106456778A CN201580032338.8A CN201580032338A CN106456778A CN 106456778 A CN106456778 A CN 106456778A CN 201580032338 A CN201580032338 A CN 201580032338A CN 106456778 A CN106456778 A CN 106456778A
Authority
CN
China
Prior art keywords
fxii
seq
injury
inhibitor
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580032338.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·克莱因施尼茨
M·诺尔特
A-L·西伦
C·阿尔贝特-魏森贝格尔
S·霍普-克雷默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CN106456778A publication Critical patent/CN106456778A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580032338.8A 2014-06-18 2015-06-18 在神经创伤性病患中使用因子xii抑制剂进行治疗 Pending CN106456778A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14172910 2014-06-18
EP14172910.3 2014-06-18
PCT/EP2015/063760 WO2015193457A1 (en) 2014-06-18 2015-06-18 Therapy using a factor xii inhibitor in a neurotraumatic disorder

Publications (1)

Publication Number Publication Date
CN106456778A true CN106456778A (zh) 2017-02-22

Family

ID=50972542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580032338.8A Pending CN106456778A (zh) 2014-06-18 2015-06-18 在神经创伤性病患中使用因子xii抑制剂进行治疗

Country Status (12)

Country Link
US (2) US20170114119A1 (enExample)
EP (1) EP3157548B1 (enExample)
JP (1) JP7109160B2 (enExample)
KR (1) KR102513050B1 (enExample)
CN (1) CN106456778A (enExample)
AU (1) AU2015276089B2 (enExample)
BR (1) BR112016029624A2 (enExample)
CA (1) CA2950988C (enExample)
DK (1) DK3157548T3 (enExample)
ES (1) ES2886859T3 (enExample)
PL (1) PL3157548T3 (enExample)
WO (1) WO2015193457A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
CA3018375A1 (en) * 2016-03-30 2017-10-05 Carin Sjolund Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
KR20230136687A (ko) * 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법
BR112020011240A2 (pt) 2017-12-15 2020-11-24 Csl Limited uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica
WO2020113084A1 (en) * 2018-11-28 2020-06-04 Oregon Health & Science University Therapeutic factor xii antibody
WO2022235551A2 (en) * 2021-05-03 2022-11-10 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101102819A (zh) * 2004-12-23 2008-01-09 Csl百灵有限公司 血栓的形成和/或稳定化的预防
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
JP2010518039A (ja) 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
EP2651451A4 (en) 2010-12-17 2014-05-21 Anthrogenesis Corp TREATMENT OF MEDULINARY LESION AND TRAUMATIC BRAIN INJURY USING PLACENTARIAN STEM CELLS
JP6109081B2 (ja) 2011-03-09 2017-04-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
RS66465B1 (sr) 2011-07-22 2025-02-28 Csl Behring Gmbh Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe
ES2714999T3 (es) 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
PL3013366T3 (pl) 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
US9587903B2 (en) 2014-02-24 2017-03-07 Brian E. Sullivan Pneumatic launcher system and method
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
KR20230136687A (ko) 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101102819A (zh) * 2004-12-23 2008-01-09 Csl百灵有限公司 血栓的形成和/或稳定化的预防
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTIANE ALBERT ET AL.: "Ischemic stroke and traumatic brain injury: The role of the kallikrein–kinin system", 《PROGRESS IN NEUROBIOLOGY》 *
HAGEDORN ET AL: "Factor XIIa Inhibitor Recombinant Human Albumin Infestin-4 Abolishes Occlusive Arterial Thrombus Formation Without Affecting Bleeding", 《CIRCULATION》 *
刘伟国 等: "《神经损伤的基础与临床》", 31 October 2008 *
张天锡 主编: "《张天锡神经外科学》", 31 January 2014, 上海交通大学出版社 *

Also Published As

Publication number Publication date
AU2015276089B2 (en) 2021-03-18
US12065481B2 (en) 2024-08-20
AU2015276089A1 (en) 2017-02-02
BR112016029624A2 (pt) 2017-10-24
WO2015193457A1 (en) 2015-12-23
US20200131248A1 (en) 2020-04-30
KR20170016503A (ko) 2017-02-13
CA2950988A1 (en) 2015-12-23
CA2950988C (en) 2024-02-06
PL3157548T3 (pl) 2022-01-17
US20170114119A1 (en) 2017-04-27
ES2886859T3 (es) 2021-12-21
KR102513050B1 (ko) 2023-03-29
JP7109160B2 (ja) 2022-07-29
DK3157548T3 (da) 2021-09-06
EP3157548A1 (en) 2017-04-26
EP3157548B1 (en) 2021-08-04
JP2017524675A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
US12065481B2 (en) Therapy using a factor XII inhibitor in a neurotraumatic disorder
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
JP7666891B2 (ja) 遠隔虚血再灌流傷害の治療および予防
KR102067394B1 (ko) 신경학적 염증성 장애의 치료를 위한 인자 ｘｉｉ 억제제
US20120231009A1 (en) Formulations of Antibody
CA3101462A1 (en) Compositions and methods for treating immune thrombocytopenia
HK1232804B (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
CA3158862A1 (en) Polypeptide inhibitors of neutrophil elastase activity and uses thereof
HK1220132B (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor
HK1201728B (en) Factor xii inhibitors for the treatment of neurological inflammatory disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication